|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Revenues | |||||
| Research and Development Revenues | |||||
| License Revenues | |||||
| Milestone Revenues | |||||
| License and Milestone Revenues | |||||
| Collaboration Revenues | |||||
| Realization of Revenue Participation Right Purchase Agreement | |||||
| Total revenues | |||||
| Operating expenses: | |||||
| Research and development | |||||
| General and administrative | |||||
| Total operating expenses | |||||
| Operating loss | |||||
| Interest expense | |||||
| Loss on extinguishment of debt | |||||
| Non-cash interest expense on liabilities related to revenue participation right purchase agreements | |||||
| Interest and other income, net | |||||
| Change in fair value of derivative liabilities | |||||
| Change in fair value of liabilities related to RPI Transactions | |||||
| Debt conversion expense | |||||
| Net loss | |||||
| Net loss per share - basic | |||||
| Net loss per share - diluted | |||||
| Weighted-average number of shares used in computing net loss per share - basic | |||||
| Weighted-average number of shares used in computing net loss per share - diluted | |||||
| Other comprehensive (loss) gain: | |||||
| Unrealized (loss) gain on available-for-sale securities, net | |||||
| Foreign currency translation adjustments | |||||
| Comprehensive loss | |||||
Loading...
